[COLOR="#000000"]Boehringer Ingelheim has signed with Zhangjiang Biotech & Pharmaceutical Base Development Company in Pudong, Shanghai a strategic alliance agreement and contract to build a cGMP biopharmaceuticals facility.
The new site will provide full range of development and clinical services to Chinese and multi-national customers. It will become the first facility established by a leading international biopharmaceuticals manufacturer in China utilizing mammalian cell culture technology.
The facility set up will include technical process development and cGMP manufacturing which will be ready for operations early 2016.
Boehringer Ingelheim plans an investment of over 35 million EUR. The project will create up to 65 job opportunities with high qualification standards.
“Our partnership with ZJ Base Company is an important step in our global China strategy as it opens a further opportunity for Boehringer Ingelheim to participate in the growing demand for high quality biopharmaceuticals in China,” stated Christian Boehringer, Chairman of the Shareholders Committee. “Shanghai is our ideal partner with its advantages in investment environment, service system and talent resources.[/color]”